What is Tarveda Therapeutics?
Tarveda Therapeutics is a biotechnology company focused on developing innovative therapies. While the provided description is generic and appears to be unrelated to the company's actual business, Tarveda's funding history, particularly its Series D round of $30 million in January 2017, indicates a company in a scaling phase, likely advancing its drug development pipeline and clinical trials. The consistent backing from prominent venture capital firms suggests a strong focus on therapeutic innovation.
How much funding has Tarveda Therapeutics raised?
Tarveda Therapeutics has raised a total of $94M across 6 funding rounds:
Series A
$2.8M
Private Equity
$1M
Series B
$21M
Series C
$25.5M
Series D
$30M
Unspecified
$13.6M
Series A (2011): $2.8M with participation from Flagship Ventures and New Enterprise Associates
Private Equity (2014): $999K led by New Enterprise Associates and Flagship Ventures
Series B (2015): $21M supported by Eminent Venture Capital, NanoDimension, New Enterprise Associates, and Flagship Ventures
Series C (2016): $25.5M featuring NanoDimension, New Enterprise Associates, Novo A/S, and Flagship Ventures
Series D (2017): $30M backed by Versant Ventures, Novo A/S, Flagship Pioneering, NanoDimension, and New Enterprise Associates
Unspecified (2019): $13.6M, investors not publicly disclosed
Key Investors in Tarveda Therapeutics
Versant Ventures
Versant Ventures is a venture capital firm specializing in building and funding innovative biotechnology companies globally. With substantial assets under management, they have a strong track record of successful IPOs and M&A transactions, leveraging their extensive expertise in venture capital, pharmaceuticals, and biotechnology.
Novo A/S
Novo Holdings, a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, was established in 1999 and is headquartered in Hellerup, Denmark. They are a significant backer in the life sciences sector.
Flagship Pioneering
Flagship Pioneering, founded in 1999 and based in Cambridge, Massachusetts, is a company of scientists and professionals dedicated to building companies that transform human health and sustainability through pioneering innovation.
What's next for Tarveda Therapeutics?
With a history of substantial investment, Tarveda Therapeutics is positioned for continued development and potential market expansion. The major strategic investment signifies a pivotal moment, likely enabling the company to accelerate its research and development efforts, pursue regulatory approvals, and scale its operations. Future growth will likely depend on successful clinical outcomes and strategic partnerships within the pharmaceutical and biotechnology sectors.
See full Tarveda Therapeutics company page
